201. Ten-year experience of esophageal endoscopic submucosal dissection of superficial esophageal neoplasms in a single center.
- Author
-
Park HC, Kim DH, Gong EJ, Na HK, Ahn JY, Lee JH, Jung KW, Choi KD, Song HJ, Lee GH, Jung HY, and Kim JH
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Disease-Free Survival, Endoscopic Mucosal Resection adverse effects, Endoscopic Mucosal Resection mortality, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Esophageal Squamous Cell Carcinoma, Esophagectomy adverse effects, Esophagectomy mortality, Esophagoscopy adverse effects, Esophagoscopy mortality, Feasibility Studies, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Postoperative Complications etiology, Retrospective Studies, Risk Factors, Seoul, Time Factors, Treatment Outcome, Carcinoma, Squamous Cell surgery, Endoscopic Mucosal Resection methods, Esophageal Neoplasms surgery, Esophagectomy methods, Esophagoscopy methods
- Abstract
Background/aims: Endoscopic submucosal dissection (ESD) of a superficial esophageal neoplasm (SEN) is a technically difficult procedure. We investigated the clinical outcomes of ESD to determine its feasibility and effectiveness for the treatment of SEN., Methods: Patients who underwent ESD for SEN between August 2005 and June 2014 were eligible for this study. The clinical features of patients and tumors, histopathologic characteristics, adverse events, results of endoscopic resection, and survival were investigated., Results: ESD was performed in 225 patients with 261 lesions, including 70 cases (26.8%) of dysplasias and 191 cases (73.2%) of squamous cell carcinomas. The median age was 65 years (range, 44 to 86), and the male to female ratio was 21.5:1. Median tumor size was 37 mm (range, 5 to 85) and median procedure time was 45 minutes (range, 9 to 160). En bloc resection was performed in 245 of 261 lesions (93.9%), with complete resection in 234 lesions (89.7%) and curative resection in 201 lesions (77.0%). Adverse events occurred in 33 cases (12.6%), including bleeding (1.5%), perforation (4.6%), and stricture (6.5%). During a median follow-up period of 35.0 months (interquartile range, 18 to 62), none of the patients showed local recurrence. The 5-year overall and disease-specific survival rates were 89.7% and 100%, respectively., Conclusions: ESD is a feasible and effective procedure for the treatment of SEN based on our 10-year experience, which showed favorable outcomes., Competing Interests: No potential conflict of interest relevant to this article was reported.
- Published
- 2016
- Full Text
- View/download PDF